Alagu P Thiruvengadam

7425410, Sep 16, 2008

Apr 14, 2004

10/823647

Alagu P. Thiruvengadam - Ellicott City MD, US
Krish Chandrasekaran - Columbia MD, US

Free State Diagnostics, LLC - Ellicott City MD

C12Q 1/34
C12Q 1/00
G06F 19/00
G01N 33/48
G01N 33/50

435 4, 435 29, 435366, 424 91, 424 931, 424 937, 702 19

Changes that occur in Na+K+ ATPase regulation and therefore in the membrane potential in cells from bipolar individuals, as compared to cells from unaffected control individuals, are utilized to provide a diagnostic assay for a bipolar disorder. The diagnostic assay may also or instead exploit the similarity of cells from bipolar patients to those of people already known to have a bipolar disorder. A similar diagnostic assay is provided for diagnosing unipolar disorder. The diagnostic assays may further involve manipulation of membrane potential by incubation of cells in K+-free buffer and/or incubation with one or more compounds that alter Na+K+ ATPase activity. Although a variety of cells may be used, the diagnostic assays preferably employ lymphoblasts or whole blood cells.

7906300, Mar 15, 2011

Apr 3, 2006

11/911500

Alagu P. Thiruvengadam - Ellicott City MD, US
Krish Chandrasekaran - Columbia MD, US

PsychNostics, LLC - Ellicott City MD

C12Q 1/00
C12Q 3/00
C12Q 1/34
G01N 33/48
C12N 5/071

435 18, 435 3, 435 4, 435 29, 435366, 702 19

Changes that occur in NaK ATPase regulation and therefore in the membrane potential in cells from bipolar individuals, as compared to cells from unaffected control individuals, are utilized to provide a diagnostic assay for bipolar I and bipolar II disorders. The diagnostic assay may also or instead exploit the similarity of cells from new patients to those of people already known to have bipolar I or bipolar II disorder. A similar diagnostic assay is provided for diagnosing attention-deficit/hyperactivity disorder (ADHD) and unipolar disorder. The diagnostic assays may further involve manipulation of membrane potential by incubation of cells in K-free buffer and/or incubation with one or more compounds that alter NaK ATPase activity. Although a variety of cells may be used, the diagnostic assays preferably employ lymphoblasts or whole blood cells.

41273320, Nov 28, 1978

Nov 19, 1976

5/743490

Alagu P. Thiruvengadam - Columbia MD
Ambrose A. Hochrein - Olney MD

Daedalean Associates, Inc. - Woodbine MD

B01F 502

366131

A method and apparatus are disclosed for the homogenization of a multicomponent stream including a liquid and a substantially insoluble component, which may be either a liquid or a finely divided solid. The homogenization process is effected by passing the multicomponent, fluid stream through a turbulent shear layer having a substantial velocity gradient there-across and designed such that turbulent vortical eddies generate a cavitating flow regime. The cavitating flow regime allows the generation of vapor bubbles which move downstream into a region of pressure and violently collapse. The violent bubble collapse creates intense pressure pulses which cause the intimate intermixing of the liquid and the substantially insoluble component such that the effluent, a resulting emulsion, has an exceptionally long separation half-life with a very high emulsification coefficient. When the insoluble component is a particulate solid, the collapse of the cavitation bubbles further subdivides those particles such that the effluent is a colloidal suspension. The turbulent shear layer may be effected with a homogenizing unit having a relatively small diameter sharp-edged orifice.

41936353, Mar 18, 1980

Apr 7, 1978

5/894557

Alagu P. Thiruvengadam - Columbia MD
Ambrose A. Hochrein - Olney MD

E21C 2560
B08B 312

299 17

A process and apparatus for high speed material removal with relatively low specific energy input requirements are disclosed. The apparatus includes a system for supplying pressurized fluid at a predetermined flow rate and pressure to an orifice of predetermined diameter. The system establishes a fluid flow to an environment in which there exists cavitation downstream of the orifice. The orifice size, position relative to the surface being treated, the fluid velocity and fluid pressure are determined with reference to the erosion strength of the particular parent material to be removed so as to effect highly efficient rapid cutting, drilling, cleaning and the like. The process includes the generation of a cavitation-free fluid flow through the orifice such that a submerged cavitating flow field is established downstream of that orifice. The velocity of fluid flowing through the orifice is selected to provide a cavitation intensity which exceeds the threshold erosion intensity of the material to be removed. As the cavitation bubbles collapse, the material is removed to selectively clean, cut or drill, as required.

42312590, Nov 4, 1980

Aug 11, 1978

5/933114

Alagu P. Thiruvengadam - Columbia MD
Ambrose A. Hochrein - Olney MD

G01N 2900

73584

A non-destructive evaluation technique particularly suited for in situ testing utilizes significant changes in internal friction damping (IFD) as an indicating factor. A baseline for the specific damping capacity of an object is determined and a tolerance range is established from the baseline. Measurements of the specific damping capacity are periodically made and checked to see if they are within the tolerance range. Unexpected changes in specific damping capacity indicate the presence of an incipient flaw in the object. The evaluation technique can also be used to locate flaws, monitor crack growth and predict useful life. Apparatus for measuring specific damping capacity is also disclosed.

20190302102, Oct 3, 2019

Oct 26, 2017

16/346212

- Baltimore MD, US
Alagu P. THIRUVENGADAM - Baltimore MD, US

PsychNostics, LLC - Baltimore MD

G01N 33/50
A61K 33/06
A61K 45/06
G16H 20/10

The present invention relates to pharmaceutical combinations and compositions, and methods of using the same for treatment of Bipolar Disorder (BD). More specifically, the invention relates to combination therapies for the treatment of BD, and methods for treating BD using such therapies. The present invention also relates to methods of determining an optimal combination drug treatment therapy for BD, methods of optimizing a combination drug treatment therapy for BD, methods of optimizing dosage of a drug in a combination drug treatment therapy for BD, as well as methods for monitoring the efficacy of a combination therapy for the treatment of BD. The present invention involves analyzing the membrane potential of cells isolated from a BD patient treated with the combination therapy, and calculating a membrane potential ratio therefrom.

20190293633, Sep 26, 2019

Jun 12, 2019

16/439084

- Baltimore MD, US
Alagu P. THIRUVENGADAM - Baltimore MD, US

PsychNostics, LLC - Baltimore MD

G01N 33/50
G01N 33/68

The present invention provides methods to modulate key elements along the DAG signaling pathway as well as a diagnostic assay, device and methods of using the same to diagnose bipolar disorder (BD) and attention deficit hyperactivity disorder (ADHD). Methods to identify diagnostic markers and drug targets for BD and ADHD. Methods of identifying effective compounds responsible for membrane potentials and excitabilities influencing bipolar disorder (BD) and attention deficit hyperactivity disorder (ADHD). Methods of identifying an effective compound that modulates the activity of Ca/CaM enzyme and compounds involved in changing the K gradient across the plasma membrane thereby increasing or decreasing the membrane potential ratio (MPR™) values. The invention provides methods of identifying a compound that modulates the activity of PKC which is an important protein of the DAG signaling pathway. Methods of identifying a compound that modulates DAG and its related enzymes along the DAG signaling pathway are provided. These compounds decrease or increase the membrane potential ratio (MPR™) in BD and ADHD patients.

20170010255, Jan 12, 2017

Sep 26, 2016

15/276088

Alagu P. THIRUVENGADAM - Ellicott City MD, US

PsychNostics, LLC - Ellicott City MD

G01N 33/50

The present invention provides methods to modulate key elements along the DAG signaling pathway as well as a diagnostic assay, device and methods of using the same to diagnose bipolar disorder (BD) and attention deficit hyperactivity disorder (ADHD). Methods to identify diagnostic markers and drug targets for BD and ADHD. Methods of identifying effective compounds responsible for membrane potentials and excitabilities influencing bipolar disorder (BD) and attention deficit hyperactivity disorder (ADHD). Methods of identifying an effective compound that modulates the activity of Ca/CaM enzyme and compounds involved in changing the K gradient across the plasma membrane thereby increasing or decreasing the membrane potential ratio (MPR™) values. The invention provides methods of identifying a compound that modulates the activity of PKC which is an important protein of the DAG signaling pathway. Methods of identifying a compound that modulates DAG and its related enzymes along the DAG signaling pathway are provided. These compounds decrease or increase the membrane potential ratio (MPR™) in BD and ADHD patients.